KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.66
+0.01 (0.04%)
May 4, 2026, 4:00 PM EDT - Market closed
KalVista Pharmaceuticals Revenue
In the year 2025, KalVista Pharmaceuticals had annual revenue of $73.62M. KalVista Pharmaceuticals had revenue of $59.93M in the quarter ending December 31, 2025.
Revenue (ttm)
$73.62M
Revenue Growth
n/a
P/S Ratio
18.55
Revenue / Employee
$267,698
Employees
275
Market Cap
1.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 73.62M | - | - |
| Apr 30, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | - | - | - |
| Apr 30, 2022 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| AbCellera Biologics | 75.13M |
| Wave Life Sciences | 71.80M |
| Viridian Therapeutics | 70.85M |
| uniQure | 16.10M |
KALV News
- 5 days ago - Italian drugmaker Chiesi to buy KalVista for $1.9 billion - Reuters
- 5 days ago - Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio - Business Wire
- 5 days ago - Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion - Reuters
- 19 days ago - KalVista Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 26 days ago - KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 4 weeks ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - Business Wire
- 5 weeks ago - KalVista Pharmaceuticals Transcript: Transition period - Transcripts